Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to validate an integrated pharmacokinetic-pharmacodynamic model to administer propofol in obese patients.
Our hypothesis is that pharmacokinetic and pharmacodynamic changes occur with increasing weight and that mathematical models to administer drugs in obese patients can be developed to accurately predict dose schemes in this population.
| Condition | Intervention | Phase |
|---|---|---|
|
Obesity |
Drug: Propofol |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Supportive Care |
| Official Title: | Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients |
- Validated pharmacokinetic-pharmacodynamic model of Propofol in Obese patients [ Time Frame: During the intraoperative period and until 120 min after stopping propofol infusion ] [ Designated as safety issue: No ]
| Enrollment: | 20 |
| Study Start Date: | March 2012 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Propofol
20 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery.
|
Drug: Propofol
General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
|
Detailed Description:
Propofol is the most frequently used IV anesthetic today. Propofol TCI is commonly used for induction and maintenance of general anaesthesia in obese and non obese patients. However, current propofol PK models, used in TCI devices, were derived from studies that did not include obese patients. A controversial issue for propofol dose adjustment in this population has been the selection of an adequate size descriptor to scale PK parameters, as drug administration based on total body weight can result in overdose, and conversely, administration based on ideal body weight can result in a sub-therapeutic dose. In a previous study from our group, we developed a PK model capable of characterizing the influence of obesity on propofol disposition. The purpose of this study is to validate this model to administer propofol in obese patients.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- IMC > 35 kg m-2
- Scheduled for laparoscopic bariatric surgery
- ASA I-II patients
- Between 18 and 60 yr of age.
Exclusion Criteria:
- Patients with allergy to study drugs
- Uncontrolled hypertension
- Heart block greater than first degree
- Take any drug acting in the central nervous system within 24 hrs before surgery.
Contacts and Locations| Chile | |
| Hospital Clinico Pontificia Universidad Catolica | |
| Santiago, Region Metropolitana, Chile | |
| Principal Investigator: | Luis I Cortínez, MD | Departamento de Anestesiología, Hospital Clínico Pontificia Universidad Católica de Chile |
More Information
No publications provided
| Responsible Party: | Ignacio Cortínez F., Profesor Asociado, Departamento de Anestesiología, Pontificia Universidad Catolica de Chile |
| ClinicalTrials.gov Identifier: | NCT01596387 History of Changes |
| Other Study ID Numbers: | 11-142-Fondecyt-UC-2012 |
| Study First Received: | May 8, 2012 |
| Last Updated: | May 10, 2012 |
| Health Authority: | Chile: Institutional Review Board |
Keywords provided by Pontificia Universidad Catolica de Chile:
|
anaesthetics iv propofol pharmacokinetics pharmacodynamic |
Additional relevant MeSH terms:
|
Obesity Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Propofol Anesthetics, Intravenous |
Anesthetics, General Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Hypnotics and Sedatives |
ClinicalTrials.gov processed this record on May 16, 2013